Replies to post #151394 on Avid Bioservices Inc (CDMO)

[Frustrated]

All the posting on the Fargo issues that skips over this critical point is somewhere between irrelevant and misleading in my view.

It is not irrevalent even though they get to do a phase III trial. The mishap cost a loan, a million plus penalty, possibly a partership, millions and millions of ATM shares, credibility and a delay of over a year. If everything is now equal and just depended on approval of the trial then we would not be at $1.34. Something is still not right! All imo.

[Carboat]

It was enough! along with safety profile, for fda PIII. It also was enough of a fiasco to; lose partner, lose loan, force all-dolutive atm funding, depress share price. This pphm blunder had huge consequences and to ignore them and say all that matters is PIII approval is "irrelevent and misleading '.